OR WAIT 15 SECS
The Green Cross facility in Canada will produce intravenous immunoglobulin and albumin.
Green Cross Biotherapeutics (GCBT) began construction on its biopharmaceutical facility located on the Montreal Technoparc's Saint-Laurent Campus in Canada, the company announced on June 1, 2015. The CA$315 (US$253) million project will be the first intravenous immunoglobulin (IVIG) and albumin manufacturing plant in Canada and is one of the first accomplishments realized through the Canada-Korea Free Trade Agreement, said the company.
GCBT, part of the Green Cross Corporation headquartered in South Korea, was founded in 2014. The new facility, expected to start production in 2019, will serve as a North American hub for the distribution of a variety of therapeutic products from the Green Cross family.
"From Montreal, we will be serving the Canadian market and exporting to countries including the United States and China," said Green Cross Corporation's chairman Il-Sup Huh. "For Canadian patients and their healthcare providers, this means securing access to a local and stable source of therapeutic plasma-derived products."
GCBT is planning to recruit 200 highly qualified scientists, engineers, microbiologists, chemical engineers and other professionals, to produce and distribute plasma protein products. Products that will be manufactured in this facility include intravenous immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and albumin, used as a blood-volumizing agent and in the treatment of burns. The plant will have a floor area of 225,000 ft2.
Source: Green Cross Biotherapeutics